Cimicoxib: Antiarthritic analgesic COX-2 inhibitor

Drugs of the Future

Volumn 29, Issue 4, 2004, Pages 325-330

  Sorbera, L A ^a   Ramis, I ^b  

^a PROUS SCIENCE   (Spain)

^b Poligono Industrial Riera de Caldes   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; AUTACOID; CARBON 14; CARRAGEENAN; CELECOXIB; CIMICOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IMIDAZOLE DERIVATIVE; INDOMETACIN; ISOENZYME; KETOROLAC; MELOXICAM; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PRODRUG; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UR 14048; VALDECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EXPERIMENTAL MODEL; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; MUTAGENICITY; NEPHROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; PAIN; PAIN ASSESSMENT; PHARMACOKINETICS; QT PROLONGATION; REVIEW; STOMACH EROSION; STOMACH ULCER; TERATOGENICITY; THROMBOSIS; TOOTH PAIN;

EID: 2642569935     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.04.790967     Document Type: Review

References (20)

1. Almansa, C., González, C. (J. Uriach & Cia, S.A.), Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives. WO 03016285.
2. Almansa, C., González, C., Torres, C. (J. Uriach & Cia, S.A.). Novel imidazoles with anti-inflammatory activity. EP 1122243, WO 0023426.
3. Prous Science Drug R&D Backgrounders. Rheumatoid arthritis (online publication). Updated February 24, 2004.
4. Prous Science Drug R&D Backgrounders. Pain (online publication). Updated March 1, 2004.
5. Botting, J. Defining the role of COX-2 inhibitors in inflammatory and other diseases. Drugs News Perspect 2000, 13: 560-6.
6. Graul, A., Martel, A.M., Castañer, J. Celecoxib. Drugs Fut 1997, 22: 711-4.
7. Sorbera, L.A., Leeson, P.A., Castañer, J. Rofecoxib. Drugs Fut 1998, 23: 1287-96.
8. Sorbera, L.A., Leeson, P.A., Castañer, J., Castañer, R.M. Valdecoxib and parecoxib sodium. Drugs Fut 2001 26: 133-40.
9. Sorbera, L.A., Castañer, R.M., Silvestre, J., Castañer, J. Etoricoxib. Drugs Fut 2001, 26: 346-53.
10. Bombardier, C., Laine, L., Reicin, A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000, 343: 1520-8.
11. Gómez-Casajus, L.A., Cavalcanti, F.L., Alfón, J., Merlos, M., Garcia-Rafanell, J. A new imidazole derivative as potent, selective orally active COX-2 inhibitor. Inflamm Res 2001, 50(Suppl. 3): Abst W17/02.
12. Ramis, I., Cavalcanti, F., Alfón, J., Gómez-Casajus, L., Vericat, L., Merlos, M. The gastrointestinal safety profile of UR-8880, a new cyclooxygenase-2 inhibitor. Inflamm Res 2001, 50(Suppl. 3): Abst 066.
13. Almansa, C., Alfón, J., de Arriba, A.F. et al. Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-Diarylimidazoles. J Med Chem 2003, 46: 3463-75.
14. Paulson, S.K., Zhang, J.Y., Breau, A.P. et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 2000, 28: 514-21.
15. Nicoll-Griffith, D.A., Yergey, J.A., Trimble, L.A. et al. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). Bioorg Med Chem Lett 2000, 10: 2683-6.
16. Halpin, R.A., Geer, L.A., Zhang, K.E., Marks, T.M., Dean, D.C., Jones, A.N., Melillo, D., Doss, G., Vyas, K.P. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab Dispos 2000, 28: 1244-54.
17. Talley, J.J., Brown, D.L., Carter, J.S. et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J Med Chem 2000, 43: 775-7.
18. Karim, A., Laurent, A., Slater, M.E., Kuss, M.E., Qian, J., Crosby-Sessoms, S.L., Hubbard, R.C. A pharmacokinetic study of intramuscular (im.) parecoxib sodium in normal subjects. J Clin Pharmacol 2001, 41: 1111-9.
19. Chauret, N., Yergey, J.A., Brideau, C., Friesen, R.W., Mancini, J., Riendeau, D., Silva, J., Styhler, A., Trimble, L.A., Nicoll-Griffith, D.A. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 2001, 11: 1059-62.
20. Rigau D., De la Cruz, G., Peña, J., Carbó, M., Ramis, I., Izquierdo, I, UR-8880, a new potent COX-2 inhibitor: First administration into man to assess its tolerability, pharmacokinetics and pharmacodynamics. Ann Rheum Dis 2003, 62(Suppl I): 413.